1. Home
  2. PROF vs TNXP Comparison

PROF vs TNXP Comparison

Compare PROF & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

HOLD

Current Price

$6.60

Market Cap

189.2M

Sector

Health Care

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$19.64

Market Cap

197.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PROF
TNXP
Founded
N/A
2007
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
189.2M
197.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PROF
TNXP
Price
$6.60
$19.64
Analyst Decision
Strong Buy
Buy
Analyst Count
1
1
Target Price
$11.00
$70.00
AVG Volume (30 Days)
100.8K
802.7K
Earning Date
11-13-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,297,000.00
$10,299,000.00
Revenue This Year
$64.23
$14.79
Revenue Next Year
$113.06
$933.49
P/E Ratio
N/A
N/A
Revenue Growth
67.94
N/A
52 Week Low
$3.76
$6.76
52 Week High
$8.36
$130.00

Technical Indicators

Market Signals
Indicator
PROF
TNXP
Relative Strength Index (RSI) 57.49 59.63
Support Level $6.09 $15.10
Resistance Level $7.04 $16.18
Average True Range (ATR) 0.42 1.39
MACD 0.02 0.74
Stochastic Oscillator 70.27 93.12

Price Performance

Historical Comparison
PROF
TNXP

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: